News
Favor teams up with imaware to provide at-home STI testing
More than nine million women in the US are diagnosed with an STI each year

The healthtech testing company imaware has partnered with the digital healthcare platform Favor to offer at-home sexually transmitted infections (STI) testing.
The at-home STI test aims to give women an accurate picture of their reproductive health and improve patient experience.
STIs impact one in five Americans. The pandemic has further exacerbated the prevalence of STIs in the US, with the CDC reporting that the rates of gonorrhea, syphilis, and congenital syphilis surpassing 2019 levels.
The American Journal of Preventive Medicine has also found the pandemic had adverse effects on sexual health screening, causing declines in testing.
The Texas-based company imaware has developed its first at-home STI test in an effort to encourage more women to get tested.
The test measures eight key biomarkers to screen for STIs like: gonorrhea, chlamydia, trichomoniasis, mycoplasma genitalium (MG), ureaplasma urealyticum, syphilis and herpes.
“Our patients have a diverse set of needs when it comes to their reproductive care and we want to empower them by offering the tools they need to live healthy, happy lives,” said Liz Meyerdirk, CEO of Favor.
“imaware has been a trusted partner throughout this process — from building a customised STI test kit to creating a seamless back-end experience so that our patients can easily view their results and next steps.
“This test will be instrumental in enabling our patients to detect STIs earlier from the comfort of their home,” she added.
Jani Tuomi, founder of imaware, said: “Favor deeply understands women’s health and how unique each patient’s journey can be.
“STI testing is more than just a box and what’s inside. It’s critical to understand the worries and challenges that patients face when they go to get tested, from cost of testing to sensitivities around discretion.
“imaware was created to make scientifically validated tools for screening and monitoring health more accessible and convenient,” Tuomi added.
“We are extremely proud to be partnering with Favor, a company closely aligned with our own mission.”
Favor patients will be eligible to purchase the STI test immediately through Favor’s digital platform.
Menopause
Perimenopause misinformation ‘putting women at risk’
Insight
Early PET scan could chemo response in aggressive breast cancer – study
News
Femtech World reveals startup of the year shortlist

We are excited unveil the three finalists competing for one of the Femtech World Awards’ most coveted honours: the Startup of the Year Award, sponsored by Future Fertility.
This award celebrates an early-stage company making a bold impact in women’s health through innovation, vision and execution.
The winner will be announced at our virtual ceremony on 19 June, with the decision made by a representative from category sponsor Future Fertility.
Congratulations to the shortlist and thank you to everyone who entered or nominated.
Startup of the Year Shortlist

Hello Inside is the first women’s health AI company to turn daily metabolic signals into outcomes women feel and healthcare systems reimburse.
Women’s health has long been under-researched, and current AI benchmarks fail on women’s health questions roughly sixty percent of the time.
Hello Inside built the architecture to close that gap.
Across four years and 12,000+ validated metabolic profiles, three in four women improve at least one symptom within ninety days.
They lose four kilograms in three months, moving from overweight into the healthy range. In a clinical study with Alisa Vitti’s Flo Living, 91.9 per cent reduced PMS burden within sixty days.


U-Ploid is an early-stage biotechnology company tackling one of the most fundamental challenges in fertility care: the sharp, age-related decline in egg quality that limits outcomes across IVF and egg freezing.
While much of the field focuses on improving assessment and selection, U-Ploid is developing a first-in-class therapeutic approach designed to improve egg quality itself by addressing the biological causes of age-related chromosomal errors.
Supported by strong preclinical evidence and now advancing into human studies, U-Ploid combines scientific rigour, regulatory discipline and long-term vision to help redefine what is possible in fertility care.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Events4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Fertility4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS














